Eikon Therapeutics, Inc.

Conduct first interim analysis to select the EIK1001 dose for TeLuRide-008

Deadline not yet reached (430 days left)

Announced: 26 Oct 2026
Due: 31 Dec 2027

Deadline
Met
Late
Not met
Today

What the company said

“Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.”

SourceEikon Therapeutics, Inc. Form 8-K press release, 2026-10-26
FilingSEC filing index
Deadline as statedin the second half of 2027
Deadline used31 Dec 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-EIKN-025295
Cite as https://keptindex.org/c/KI-C-2026-EIKN-025295/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Conduct
Deliverable: First interim analysis for dose selection in TeLuRide-008
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Eikon Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-EIKN-025295 · Corrections policy